Wegovy is a registered trademark of Novo Nordisk A/S. It is an FDA-approved prescription medicine. Whether Medicare pays depends on the prescribed use, the person's drug coverage, and the rules of the applicable Medicare pathway.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, also called MTC, and in people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Major serious risks include pancreatitis, gallbladder disease, low blood sugar when used with certain diabetes medicines, kidney injury due to dehydration, severe stomach problems, serious allergic reactions, diabetic eye complications, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation. Common side effects include nausea, diarrhea, vomiting, constipation, and stomach pain. Read the complete official Prescribing Information and Medication Guide. A licensed clinician should weigh the potential benefits and risks for each person.
The short answer is that Medicare may pay through Part D for a coverable medical use. In 2026, certain beneficiaries may also qualify for the separate, temporary Medicare GLP-1 Bridge. Neither route is automatic.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
When Part D may pay
Basic Medicare Part D has generally excluded drugs when they are used only for weight loss. A medicine that is also used for weight management may still be coverable when it is prescribed for another medically accepted indication.
Wegovy is indicated to reduce the risk of major cardiovascular events in adults who have established cardiovascular disease and either obesity or overweight. Its current labeling also includes other indications. The exact prescribed use matters because Medicare does not decide coverage from the product name alone.
CMS gives cardiovascular risk reduction as an example of a Wegovy use that belongs in the Part D pathway. Even then, a plan can apply its formulary process and utilization rules. These may include prior authorization, quantity limits, or use of a network pharmacy.
The plan decides whether the request meets its terms and what it pays. A prescription, diagnosis, or place on a formulary does not promise that a claim will be approved.
The Medicare GLP-1 Bridge
The Medicare weight-loss drug page describes a temporary Medicare GLP-1 Bridge available from July 1, 2026, through December 31, 2027. The Bridge operates outside the normal Part D benefit payment flow and is available nationwide to certain people with qualifying Medicare drug coverage.
Wegovy injection and tablets are included. A beneficiary must meet the program's plan and clinical criteria. A provider must send a valid prescription to the pharmacy and, when requested, submit prior authorization information. The provider must also certify that the medicine is used with an ongoing lifestyle program involving nutrition and physical activity.
The Bridge is intended for eligible weight-management prescriptions. If the prescription is for a use that can be covered through basic Part D, CMS directs it to the Part D plan instead. Someone who already received a GLP-1 drug through Part D in 2026 may also be excluded from the Bridge.
Under current CMS terms, the Bridge has a $50 monthly medication copay for an eligible beneficiary. This is not a Body Good service fee, and it is not available to everyone. CMS states that the $50 does not count toward Part D true out-of-pocket costs. The program, plan, and processor determine eligibility and payment.
What to ask before relying on coverage
Start with the number on the Medicare drug plan member card. Give the representative the exact prescription and prescribed indication. Ask whether it should be reviewed by the plan under Part D or by the Medicare GLP-1 Bridge processor.
Then ask these practical questions:
- Is prior authorization required?
- What clinical records or diagnosis information must the prescriber provide?
- Is the prescribed form on the formulary?
- Which pharmacies can process the claim?
- What copay, coinsurance, or deductible applies?
- How can the member request a written coverage decision?
Medicare explains that drug plans may use prior authorization, step therapy, and quantity limits. Its official drug-plan rules also explain how a member or prescriber can ask for an exception. Approval of an exception is not assured.
Keep the date, representative's name, and call reference number. Coverage statements made before a claim is reviewed are estimates, not payment guarantees.
Separate each kind of cost
There may be several different charges. A Part D premium, deductible, medication copay or coinsurance, clinical service fee, and outside laboratory charge are not the same thing.
Body Good's $139 per month price is a Body Good service fee for the program described during intake. It covers the stated clinical and support services. It is not the price of medication. Medication cost is separate and not included. The fee is not a quote for any individual. Eligibility is determined by a clinician.
Medicare coverage for medication does not establish Medicare coverage for Body Good's service fee. Confirm the service fee and pharmacy medication charge separately. If a clinician orders outside laboratory work, ask whether that creates another charge.
How Body Good can help
Body Good can provide a clinical evaluation, follow-up care, coverage support, and help with paperwork requested by a plan or program. Coverage support is assistance with the process. Approval and payment are determined by Medicare, the drug plan, or the applicable program, not by Body Good.
A clinician may decide that a prescription is not appropriate. If one is written, a pharmacy or another authorized dispensing provider supplies the medication and charges for it.
This website is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. All intake and checkout take place on joinbodygood.com.
Frequently asked questions
Does Medicare pay for Wegovy used only for weight management?
Some beneficiaries may qualify for the temporary Medicare GLP-1 Bridge if they have qualifying Part D coverage and meet all program criteria. Basic Part D and the Bridge are different payment routes. Medicare or the applicable plan makes the decision.
Does Medicare Part B pay for it?
Wegovy is generally a self-administered outpatient prescription, so questions usually concern Part D or the Bridge rather than Part B. A beneficiary should confirm the correct benefit directly with Medicare and the plan.
Can Body Good guarantee Medicare payment?
No. Body Good can assist with benefit checks and requested paperwork, but it cannot promise eligibility, approval, or payment. Begin Body Good's secure clinical intake to provide information for review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.